Relmada Therapeutics, Inc. - ROE
RLMD
Price:
$5.14
Market Cap:
$539.13M
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquarter...[Read more]
Industry
Biotechnology
IPO Date
2014-06-20
Stock Exchange
NASDAQ
Ticker
RLMD
PE Ratio
[-4.72]
ROE
[-71.22%]
Current Ratio
[18.26]
Dividend Yield
[0%]
Enterprise Value
[529.36M]
Dividend History
The ROE as of July 2026 (TTM) for Relmada Therapeutics, Inc. (RLMD) is -71.22%
According to Relmada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -71.22%. This represents a change of 42.34% compared to the average of -50.04% of the last 4 quarters.
Relmada Therapeutics, Inc. (RLMD) Historical ROE (quarterly & annually)
How has RLMD ROE performed in the past?
The mean historical ROE of Relmada Therapeutics, Inc. over the last ten years is -114.42%. The current -71.22% ROE has changed -37.75% with respect to the historical average. Over the past ten years (40 quarters), RLMD's ROE was at its highest in in the March 2018 quarter at 138.26%. The ROE was at its lowest in in the March 2019 quarter at -566.79%.
Average
-114.42%
Median
-89.08%
Minimum
-430.53%
Maximum
162.54%
Relmada Therapeutics, Inc. (RLMD) ROE by Quarter and Year
Discovering the peaks and valleys of Relmada Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 919.15%
Maximum Annual ROE = 162.54%
Minimum Annual Increase = -239.95%
Minimum Annual ROE = -430.53%
| Year | ROE | Change |
|---|---|---|
| 2025 | -66.33% | -70.54% |
| 2024 | -225.15% | 94.54% |
| 2023 | -115.74% | 3.50% |
| 2022 | -111.83% | 85.20% |
| 2021 | -60.38% | 7.22% |
| 2020 | -56.31% | 334.13% |
| 2019 | -12.97% | -94.30% |
| 2019 | -227.47% | -239.95% |
| 2018 | 162.54% | -137.75% |
| 2017 | -430.53% | 919.15% |
Relmada Therapeutics, Inc. (RLMD) Average ROE
How has RLMD ROE performed in the past?
The current ROE of Relmada Therapeutics, Inc. (RLMD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-135.74%
5-year avg
-115.89%
10-year avg
-114.42%
Relmada Therapeutics, Inc. (RLMD) ROE vs. Peers
How is RLMD’s ROE compared to its peers?
Relmada Therapeutics, Inc.’s ROE is greater than Acrivon Therapeutics, Inc. Common Stock (-64.43%), greater than PMV Pharmaceuticals, Inc. (-68.98%), greater than Immunic, Inc. (-220.75%), greater than TScan Therapeutics, Inc. (-91.94%), less than Vaxart, Inc. (61.43%), greater than Lite Strategy, Inc. (-90.81%), less than Fortress Biotech, Inc. (163.88%), greater than Repare Therapeutics Inc. (-37.24%), greater than Cibus, Inc. (-225.59%), greater than Adicet Bio, Inc. (-80.35%),
| Company | ROE | Market cap |
|---|---|---|
| -64.43% | $61.21M | |
| -68.98% | $57.06M | |
| -220.75% | $177.76M | |
| -91.94% | $45.29M | |
| 61.43% | $116.18M | |
| -90.81% | $32.37M | |
| 163.88% | $111.28M | |
| -37.24% | $114.24M | |
| -225.59% | $88.25M | |
| -80.35% | $77.59M |
Build a custom stock screener for Relmada Therapeutics, Inc. (RLMD) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Relmada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Relmada Therapeutics, Inc. (RLMD) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Relmada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Relmada Therapeutics, Inc.'s ROE?
How is the ROE calculated for Relmada Therapeutics, Inc. (RLMD)?
What is the highest ROE for Relmada Therapeutics, Inc. (RLMD)?
What is the 3-year average ROE for Relmada Therapeutics, Inc. (RLMD)?
What is the 5-year average ROE for Relmada Therapeutics, Inc. (RLMD)?
How does the current ROE for Relmada Therapeutics, Inc. (RLMD) compare to its historical average?